Zonagen (zona) - good buy? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Zonagen (zona) - good buy?

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: BigKNY3 who wrote (864)	11/22/1997 10:54:00 AM
From: Cacaito	Read Replies (3) of 7041

BigKNY3, Most companies publish in journals long before product approval. Many scientists careers depend on publications and they are not patient about it. 3 to 18 months to published? it depends if the company sees a benefit from publications. Xoma has dozens of articles (if not hundreds) on their E5 and BPI products, both at least 1 year away from approval. Last one in The Lancet about BPI (last issue Nov 97). Scios published about Atrial Natriuretic Factor in early 97 and it is far from approval.(NEJM). Amgen published in the NEJM about Megakaryocyte Stimulating Factor in 97 and it is not FDA submitted yet. It is for the benefit of a small biotech to have publications on their research.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next